Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study

Martijn J. Tillya, MD, Sven Geurtsa, MD, Samantha J. Donkelb, MD, M. Arfan Ikrama, PhD, Natasja M.S. de Groota, PhD, Moniek P.M. de Maatb, PhD, *Maryam Kavousia, PhD

a Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
b Department of Hematology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
c Department of Cardiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

Corresponding author: Maryam Kavousi
Erasmus MC, University Medical Center Rotterdam, office Na-2714
PO Box 2040, 3000 CA Rotterdam, The Netherlands
Telephone Number: +31 10 7043997
Email: m.kavousi@erasusmc.nl

Journal: Clinical Research in Cardiology
Online Resource 2. Flowchart for the inclusion of the study population

Participates of RS-I-3 and RS-II-1 (N = 10,994)

Excluded:
- Participants without informed consent (N = 251)
- Participants with prevalent AF (N = 631)

Participates in RS-I-3 and RS-II-1, free of AF at baseline (N = 10,112)

Participants with missing data (N = 3,938)

Participates included in analyses (N = 6,174)